Okomera has raised $11.0M in total across 1 funding round.
Okomera's investors include Balderton Capital, Resonance VC.
Okomera is a biotech startup founded in 2020 that develops automated, miniaturized platforms for high-throughput organoid screening in oncology drug discovery and personalized cancer treatments.[1][2][3] Its core product, the Automated Desktop Organoid Screening Instrument, uses proprietary microfluidic chips, AI-powered analysis, and 3D technology to generate organoids from as few as 50 cells, enabling multiplexing of over 100 conditions, co-culture of multiple cell types, and testing of patient samples or biopsies for efficient drug screening.[2][3] Okomera serves pharmaceutical companies, clinical researchers, and cancer centers by accelerating preclinical drug testing, reducing costs, and improving predictivity from target validation to functional precision medicine, with current use in patient sample testing and expansion into clinical trials.[1][2]
The company addresses key challenges in oncology research, such as the need for scalable, reproducible 3D models that preserve scarce patient samples while screening multiple therapies to identify optimal treatments.[1][2][3] With under 25 employees, headquarters in Paris, and less than $5 million in funding across one round, Okomera shows early growth momentum through collaborations like with Gustave Roussy and presentations at SLAS 2025.[2][4]
Okomera spun out from École Polytechnique in 2020, building on a decade of research at the Pasteur Institute and École Polytechnique into microfluidics and organoid technology.[2] CEO Sidarth Radjou leads the Paris-based team, driving its focus on automating personalized tumor biopsy studies.[1][2] The idea emerged from advancing 3D cell culture models to make high-throughput drug screening feasible on a desktop scale, starting with patient-derived xenografts (PDX) and progressing to biopsy samples for real-world oncology applications.[2] Early traction includes partnerships with clinicians at Gustave Roussy, demonstrating reproducible organoid generation and drug screening, positioning Okomera as a tool for both pharma innovation and precision medicine.[2]
Okomera rides the wave of functional precision medicine and AI-enhanced drug discovery, where 3D organoids outperform traditional 2D models in predicting patient responses to cancer therapies.[1][2] Timing aligns with surging demand for personalized oncology amid rising cancer incidence and pressure to cut drug development timelines—its platform addresses inefficiencies in preclinical testing by boosting throughput and predictivity.[2][3] Market forces like advancements in microfluidics, AI analytics, and biopharma's shift to patient-derived models favor Okomera, enabling pharma to validate targets faster and clinicians to tailor treatments.[2][4] By influencing ecosystem collaborations (e.g., with Gustave Roussy) and events like SLAS, it accelerates innovation from bench to bedside, potentially standardizing organoid screening in global cancer centers.[1][2]
Okomera is poised to expand its platform from PDX models to routine biopsy screening in clinical trials, targeting installations in cancer centers and deeper pharma integrations for high-impact drug discovery.[1][2] Trends like AI-driven biology, miniaturized biotech tools, and precision oncology will propel growth, especially as regulatory pushes for better preclinical predictivity intensify. Its influence may evolve from niche innovator to ecosystem enabler, powering personalized treatments that improve patient outcomes worldwide—cementing its role as the engine for next-gen cancer therapies.[1][3]
Okomera has raised $11.0M across 1 funding round. Most recently, it raised $11.0M Seed in December 2023.
| Date | Round | Lead Investors | Other Investors |
|---|---|---|---|
| Dec 1, 2023 | $11.0M Seed | Balderton Capital, Resonance VC |
